Founded in 2002,
AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 22 production and R&D facilities able to manufacture
both diagnostics and therapeutic MNM products, and has over 450 employees in 13 countries (France, Italy, UK, Germany, Switzerland,
Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015
(+26.8% vs. 2014) and sales of €54.6 million for 1H 2016 (+26.9% vs. 1H15). AAA is listed on the Nasdaq Global Select Market
under the ticker “AAAP”. For more information, please visit: www.adacap.com.
Molecular Nuclear Medicine (“MNM”)
Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images
of organs and lesions and to treat various diseases, such as cancer. The technique works by injecting targeted radiopharmaceuticals
into the patient’s body that accumulate in the organs or lesions and reveal specific biochemical processes. Molecular Nuclear
Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single
Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer,
cardiovascular diseases, neurological disorders and other diseases in their early stages.
Statement Regarding Forward-Looking Statements
release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press
release, including statements regarding the Company's strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future
events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments
to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies,
the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product
candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates;
our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera® and other chemical
compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery
of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products
or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera® and our
other products or product candidates; our estimates regarding the market opportunity for Lutathera®, our other
product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products;
our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales,
marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries
where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general
economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities
laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.